 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| 12» |
- || caficrestat (AT-001) / Applied Therap, ninerafaxstat (IMB-101) / Imbria Pharma, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
Review, Journal: "Emerging clinical approaches in diabetic cardiomyopathy: insights from clinical trials and future directions". (Pubmed Central) - Sep 10, 2024
These treatments improve myocardial glucose absorption, address dysregulated glucose and lipid metabolism, and lower heart failure and cardiovascular events. Further research is needed to confirm effectiveness and safety.
- govorestat (AT-007) / Applied Therap
Results of the ACTION-Galactosemia Kids Study, a Phase 3 Double-Blind Placebo Controlled Study Evaluating the Effects of Govorestat on Long- Term Clinical Outcomes in Pediatric Patients with Classic Galactosemia (Magnolia Auditorium | Level -1) - Aug 21, 2024 - Abstract #SSIEM2024SSIEM_1094;
Further research is needed to confirm effectiveness and safety. Sponsored by Applied Therapeutics
- govorestat (AT-007) / Applied Therap
Development of Govorestat (AT-007), the First Potential Treatment for Patients with Classic Galactosemia (Magnolia Auditorium | Level -1) - Aug 21, 2024 - Abstract #SSIEM2024SSIEM_1091;
Learnings on Classic Galactosemia from the first longitudinal study in children will be discussed, such as the progressive worsening of clinical function and widening gap between Classic Galactosemia patients and their normative peers. The effects of govorestat (a CNS penetrant aldose reductase inhibitor) on galactitol (a toxic metabolite of galactose formed in patients with Classic Galactosemia) and the effects of govorestat on long-term clinical outcomes will be presented.
- | govorestat (AT-007) / Applied Therap
Trial completion date, Trial primary completion date: Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia (clinicaltrials.gov) - Jul 30, 2024
P2/3, N=47, Active, not recruiting, Sponsor: Applied Therapeutics, Inc.
The effects of govorestat (a CNS penetrant aldose reductase inhibitor) on galactitol (a toxic metabolite of galactose formed in patients with Classic Galactosemia) and the effects of govorestat on long-term clinical outcomes will be presented. Trial completion date: Sep 2023 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2024
- || govorestat (AT-007) / Applied Therap
P1/2 data, PK/PD data, Journal: Safety, Pharmacokinetics, and Pharmacodynamics of the New Aldose Reductase Inhibitor Govorestat (AT-007) After a Single and Multiple Doses in Participants in a Phase 1/2 Study. (Pubmed Central) - Jul 11, 2024
P1/2
Govorestat did not affect galactose or Gal-1p levels. In conclusion, govorestat displayed a favorable safety, PK, and PD profile in humans, and reduced galactitol levels in the same magnitude (?50%) as in a rat model of CG that demonstrated an efficacy benefit on neurological, behavioral, and ocular outcomes.
- | caficrestat (AT-001) / Applied Therap
Journal: Randomized Trial of a Selective Aldose (Pubmed Central) - Jul 3, 2024
P3
In conclusion, govorestat displayed a favorable safety, PK, and PD profile in humans, and reduced galactitol levels in the same magnitude (?50%) as in a rat model of CG that demonstrated an efficacy benefit on neurological, behavioral, and ocular outcomes. Among individuals with DbCM and impaired exercise capacity, treatment with AT-001 for 15
- || Review, Journal: Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference. (Pubmed Central) - Jun 3, 2024
The AEGIS-II randomized patients with type 1 myocardial infarction (MI) with multivessel coronary artery disease and additional CV risk factors and found no benefit in major adverse CV events (MACE) with CSL112, an apolipoprotein A1 infusion shown to increase cholesterol efflux capacity. The Bridge-TIMI 73a trial showed a significant reduction in triglyceride (TG) levels with olezarsen, an antisense mRNA, in patients with moderate hyperTG with elevated CV risk...The VICTORIAN-INITIATE trial showed efficacy and safety in early use of inclisiran in patients with ASCVD who did not reach target LDL-C?<?70
- caficrestat (AT-001) / Applied Therap
Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical diabetic cardiomyopathy (Station 2 - Research Gateway) - May 14, 2024 - Abstract #ESC2024ESC_2283;
Among highly selected patients with subclinical DbCM, elevated NT-proBNP concentrations are associated with worse health status, lower activity levels, and reduced functional capacity, but not with cardiac structural abnormalities. These findings suggest that regardless of cardiac structural abnormalities, biomarker concentrations reflect important deterioration in functional capacity in affected individuals.
- | AT-003 / Applied Therap
Journal: Complete genome sequence of Cellulomonas sp. strain ATA003. (Pubmed Central) - May 2, 2024
strain ATA003 was isolated from the endemic cactus Maihueniopsis domeykoensis seeds collected in the Coastal Atacama Desert, Chile. Here, we present a circular genome with a size of 4,084,881 bp and a GC content of 73.8% obtained by Nanopore sequencing.
- govorestat (AT-007) / Applied Therap
Exit Interviews with Caregivers of Pediatric Patients with Classic Galactosemia Demonstrate the Meaningfulness of Changes in the ACTION-Galactosemia Kids Trial (MTCC - Exhibit Halls DE) - Jan 10, 2024 - Abstract #ACMG2024ACMG_901;
Exit interview data was consistent with Caregiver Global Impression of Severity and Global Impression of Change data. The caregiver exit interview results support the clinical meaningfulness of the treatment effect of govorestat in children with CG.
- |||| govorestat (AT-007) / Applied Therap
New P3 trial: A Sequential, Two-Part Study to Evaluate the Clinical Benefit, Safety, Pharmacokinetics, and Pharmacodynamics of AT-007 in Pediatric Patients with Classic Galactosemia (CG) (EUDRACT) - Dec 22, 2023
P3, N=47, , Sponsor: Applied Therapeutics Inc.
- |||| govorestat (AT-007) / Applied Therap
Enrollment closed: INSPIRE: Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency (clinicaltrials.gov) - Sep 25, 2023
P2/3, N=56, Active, not recruiting, Sponsor: Applied Therapeutics, Inc.
The caregiver exit interview results support the clinical meaningfulness of the treatment effect of govorestat in children with CG. Recruiting --> Active, not recruiting
- govorestat (AT-007) / Applied Therap
Consistent long-term clinical benefit with govorestat treatment: results of the ACTION-Galactosemia Kids trial (Oren 3 (ICC),Oren 4 (ICC)) - Jul 6, 2023 - Abstract #SSIEM2023SSIEM_276;
Improvement in galactitol level was sustained throughout the trial with no impact on Gal-1p or galactose. Govorestat was generally safe and well tolerated, with no treatment-related SAEs.
- AT-001 / Applied Therap
N-Terminal Pro-B Type Natriuretic Peptide Concentrations in Diabetic Cardiomyopathy (Poster Halls B-C; [Board No. 450]) - Apr 10, 2023 - Abstract #ADA2023ADA_2569;
P3
The ARISE-HF study (NCT04083339) is evaluating efficacy of AT-001, a highly selective aldose reductase inhibitor (AT-001) to improve exercise tolerance in affected patients... Among patients with DbCM, elevated NT-proBNP is associated with echocardiographic abnormalities and worse cardiac functional capacity and inversely associated with activity.
- AT-001 / Applied Therap
The Face of Diabetic Cardiomyopathy (Poster Halls B-C; [Board No. 1238]) - Apr 10, 2023 - Abstract #ADA2023ADA_597;
P3
The ARISE-HF trial is an ongoing phase 3 clinical trial evaluating the safety and efficacy of aldose reductase inhibition on exercise capacity in patients with DbCM. The baseline analysis of the study cohort provides a unique characterization of individuals with DbCM.
- AT-001 / Applied Therap
Diabetic Cardiomyopathy: baseline Characteristics of patients enrolled into the ARISE-HF trial (ePosters Station 8) - Feb 28, 2023 - Abstract #HEARTFAILURE2023HEART_FAILURE_1502;
50% of patients were female, with a mean age 67.5years. Patients enrolled had a duration of diabetes of 14 years, with excellent glycemic control at baseline (HbA1c of 6.99%).
- AT-001 / Applied Therap
Phenotypic characterization of echocardiographic abnormalities in patients with diabetic cardiomyopathy (Moderated ePosters 2) - Feb 28, 2023 - Abstract #HEARTFAILURE2023HEART_FAILURE_1341;
P3
Patients with solely diastolic abnormalities were most commonly female, treated with beta blockers, and less commonly treated with GLPRA. Patients with diastolic and mixed abnormalities had higher NT-proBNP and lower cardiac functional capacity.
- AT-001 / Applied Therap
NT-proBNP levels in diabetic cardiomyopathy: results from the ARISE-HF trial (Moderated ePosters 2) - Feb 28, 2023 - Abstract #HEARTFAILURE2023HEART_FAILURE_636;
Main baseline characteristics were similar across baseline NT-proBNP concentrations, however participants with higher NT-proBNP levels had a greater left atrial volume (LAVI) (p<0.001) and higher right ventricular systolic pressure (p=0.04) on baseline echocardiogram. Higher NT-proBNP concentrations were associated with reduced physical activity reflected in lower Physical Activity Scale for the Elderly (PASE) Score (p<0.001) and a worse quality of life defined by a lower mKCCQ score (p=0.02).
- | govorestat (AT-007) / Applied Therap
Trial completion date, Trial primary completion date: Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia (clinicaltrials.gov) - Feb 24, 2023
P2/3, N=47, Active, not recruiting, Sponsor: Applied Therapeutics, Inc.
Higher NT-proBNP concentrations were associated with reduced physical activity reflected in lower Physical Activity Scale for the Elderly (PASE) Score (p<0.001) and a worse quality of life defined by a lower mKCCQ score (p=0.02). Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Apr 2022 --> Apr 2023
- ||||| caficrestat (AT-001) / Applied Therap
Enrollment closed: ARISE-HF: Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy (clinicaltrials.gov) - Dec 8, 2022
P3, N=675, Active, not recruiting, Sponsor: Applied Therapeutics, Inc.
Trial completion date: Jun 2023 --> Sep 2023 | Trial primary completion date: Apr 2022 --> Apr 2023 Recruiting --> Active, not recruiting
- | AT-001 / Applied Therap
Journal: Rationale and Design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in Patients with High-Risk Diabetic Cardiomyopathy. (Pubmed Central) - Nov 15, 2022
P3
AT-001 is a novel investigational highly specific ARI with higher binding affinity and greater selectivity than previously studied ARIs...Additional endpoints include percentage of patients progressing to overt HF, health status metrics, echocardiographic measurements, and changes in cardiac biomarkers. This report describes the rationale and study design of ARISE-HF.
- | AT-001 / Applied Therap, Kinedak (epalrestat) / Ono Pharma
Journal: CADD Studies in the Discovery of Potential ARI (Aldose Reductase Inhibitors) Agents for the Treatment of Diabetic Complications. (Pubmed Central) - Aug 24, 2022
AR inhibitors (ARI) have been widely discussed in the literature, for example, Epalrestat is currently the only ARI used to treat patients with diabetic neuropathy in Japan, India, and China...AT-001, an AR inhibitor, is now being tested in COVID-19 to see how safe and effective it is at reducing inflammation and cardiac damage...New data shows that diabetes and obesity are among the strongest predictors of COVID-19 hospitalization. Patients and risk factors for severe morbidity and mortality of COVID- 19.
- caficrestat (AT-001) / Applied Therap
Diabetic Cardiomyopathy is Associated With Worsening of Quality of Life Long Before the Development of Overt Heart Failure: Lessons From the Baseline Analysis of the Arise-Hf Study (Zone 2, Science and Technology Hall, Level 3; Poster Board no. 2230) - Aug 11, 2022 - Abstract #AHA2022AHA_4325;
DbCM is a form of HF leading to decreased cardiac functional capacity. Many patients with DbCM have reduced their daily physical activities to mitigate the presentation of symptoms of fatigue; however, their quality of life is significantly affected by the disease even before the progression to overt HF.
- | govorestat (AT-007) / Applied Therap
New P3 trial: AT-007 in Adult Subjects With Classic Galactosemia (CG) (clinicaltrials.gov) - Jun 14, 2022
P3, N=7, Active, not recruiting, Sponsor: Applied Therapeutics, Inc.
- ||| govorestat (AT-007) / Applied Therap
Trial completion, Trial completion date: Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia (clinicaltrials.gov) - Jun 3, 2022
P1/2, N=100, Completed, Sponsor: Applied Therapeutics, Inc.
Many patients with DbCM have reduced their daily physical activities to mitigate the presentation of symptoms of fatigue; however, their quality of life is significantly affected by the disease even before the progression to overt HF. Active, not recruiting --> Completed | Trial completion date: May 2022 --> Dec 2021
- |||||||| govorestat (AT-007) / Applied Therap
New P2/3 trial: INSPIRE: Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency (clinicaltrials.gov) - May 30, 2022
P2/3, N=72, Recruiting, Sponsor: Applied Therapeutics, Inc.
- | AT-007 / Applied Therap
Journal, Interview: Qualitative interviews with adults with Classic Galactosemia and their caregivers: disease burden and challenges with daily living. (Pubmed Central) - Apr 5, 2022
The impact on both patients and caregivers underscores the severity of the unmet medical need and the importance of pharmacological intervention to halt or prevent disease progression. Any treatment that could reduce symptoms or slow functional decline would ease the burden of this condition on patients and caregivers.
- || govorestat (AT-007) / Applied Therap
Enrollment closed, Trial completion date, Trial primary completion date: Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia (clinicaltrials.gov) - Mar 3, 2022
P1/2, N=100, Active, not recruiting, Sponsor: Applied Therapeutics, Inc.
Any treatment that could reduce symptoms or slow functional decline would ease the burden of this condition on patients and caregivers. Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> May 2022 | Trial primary completion date: Jun 2020 --> Dec 2021
- |||| caficrestat (AT-001) / Applied Therap
Trial completion date, Trial primary completion date: ARISE-HF: Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy (clinicaltrials.gov) - Feb 28, 2022
P3, N=675, Recruiting, Sponsor: Applied Therapeutics, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Dec 2021 --> May 2022 | Trial primary completion date: Jun 2020 --> Dec 2021 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2023
- || govorestat (AT-007) / Applied Therap
Enrollment closed, Trial primary completion date: Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia (clinicaltrials.gov) - Feb 16, 2022
P2/3, N=47, Active, not recruiting, Sponsor: Applied Therapeutics, Inc.
Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2023 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2021 --> Apr 2022
- ||| AT-007 / Applied Therap
NDA: $APLT following discussions with the FDA, the Company has decided to hold on submitting an NDA for AT-007 for treatment of Galactosemia pending additional discussions with the agency. (Twitter) - Jan 3, 2022
- || AT-001 / Applied Therap
Clinical, Journal: A pilot open-label study of aldose reductase inhibition with AT-001 (caficrestat) in patients hospitalized for COVID-19 infection: Results from a registry-based matched-control analysis. (Pubmed Central) - Dec 16, 2021
Exposure to AT-001 was associated with a trend of reduced mortality and shortened LOS. While the observed trend did not reach statistical significance, the present study provides the rationale for investigating potential benefit of AT-001 in COVID 19 affected patients in future studies.
- | caficrestat (AT-001) / Applied Therap
Enrollment change: Cardiovascular Effects of COVID-19 (clinicaltrials.gov) - Sep 16, 2021
P2, N=81, Completed, Sponsor: NYU Langone Health
While the observed trend did not reach statistical significance, the present study provides the rationale for investigating potential benefit of AT-001 in COVID 19 affected patients in future studies. N=10 --> 81
- AT-001 / Applied Therap
[VIRTUAL] Diabetic Cardiomyopathy: An Opportunity for Clinical Intervention () - Jun 25, 2021 - Abstract #ADA2021ADA_2755;
There are currently no approved treatments for DbCM. The ARISE-HF clinical trial is currently enrolling patients and studying the ability of AT-001, a novel, potent, selective Aldose Reductase Inhibitor, to halt or prevent progression of Diabetic Cardiomyopathy.
- |||| caficrestat (AT-001) / Applied Therap
Trial completion date, Trial primary completion date: ARISE-HF: Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy (clinicaltrials.gov) - Jun 10, 2021
P3, N=675, Recruiting, Sponsor: Applied Therapeutics, Inc.
The ARISE-HF clinical trial is currently enrolling patients and studying the ability of AT-001, a novel, potent, selective Aldose Reductase Inhibitor, to halt or prevent progression of Diabetic Cardiomyopathy. Trial completion date: Sep 2023 --> Dec 2024 | Trial primary completion date: Sep 2021 --> Dec 2022
- || govorestat (AT-007) / Applied Therap
Trial completion date, Trial primary completion date: Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia (clinicaltrials.gov) - May 28, 2021
P1/2, N=86, Recruiting, Sponsor: Applied Therapeutics, Inc.
Trial completion date: Sep 2023 --> Dec 2024 | Trial primary completion date: Sep 2021 --> Dec 2022 Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Jun 2020
- | caficrestat (AT-001) / Applied Therap
Trial completion, Enrollment change: Cardiovascular Effects of COVID-19 (clinicaltrials.gov) - Feb 24, 2021
P2, N=10, Completed, Sponsor: NYU Langone Health
Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Jun 2020 Recruiting --> Completed | N=500 --> 10
- |||| AT-001 / Applied Therap
Clinical: #ARISEHF presented @CVCTForum #CVCT2020 ♦️ Diabetic CM (DbCM) has high prevalence and unmet tx needs ♦️ARISE-HF study is a global clinical trial designed to evaluate the efficacy and safety of AT-001 in a sample of DbCM/Stage B HF pts Looking forward to results! @JJheart_doc (Twitter) - Dec 5, 2020
- AT-001 / Applied Therap
[VIRTUAL] Pharmacological Inhibition of Aldose Reductase by AT001 Prevents Abnormal Cardiac Energy Metabolism and Improves Heart Function in an Animal Model of Diabetic Cardiomyopathy (OnDemand) - Sep 17, 2020 - Abstract #AHA2020AHA_3031;
Recruiting --> Completed | N=500 --> 10 AR inhibition with AT-001 prevents cardiac structural and functional abnormalities in a mouse model of DCM, and normalizes cardiac energetics by shifting cardiac metabolism towards a non-diabetic metabolic state.
- AT-001 / Applied Therap
[VIRTUAL] Addressing safety and specificity with aldose reductase inhibition: development of AT-001 for diabetic cardiomyopathy (Poster Hall) - Jul 2, 2020 - Abstract #EASD2020EASD_243;
The in-vitro safety of this agent together with the positive safety data from the phase 1/2 program, supports the ongoing pivotal study in DbCM. Clinical Trial Registration Number NCT 04083339
- AT-001 / Applied Therap
[VIRTUAL] At-001 a new aldose reductase inhibitor with improved selectivity and specificity protects from cellular damage (Poster Hall) - Jul 2, 2020 - Abstract #EASD2020EASD_240;
P3
AT-001 is currently being evaluated in a pivotal phase 2/3 study; ARISE-HF, to treat Diabetic Cardiomyopathy and prevent progression to overt heart failure and also includes sub-analyses for retinopathy and DPN. Clinical Trial Registration Number NCT04083339
- AT-001 / Applied Therap
[VIRTUAL] The ARISE-HF study: development of AT-001 for the treatment of diabetic cardiomyopathy: rationale and study design () - Jun 20, 2020 - Abstract #HEARTFAILUREI2020HEART_FAILURE-I_1211;
Other secondary endpoints include changes from baseline in NT-proBNP, modified Kansas City Cardiomyopathy Questionnaire score, and GLS, LVH, LAE, E/E’ and RVSP by echocardiography. Safety of AT-001 at both doses will also be extensively evaluated.
- AT-001 / Applied Therap
[VIRTUAL] Safety and Tolerability of the Next Generation Aldose Reductase Inhibitor (ARI) AT-001 Supports Initiation of the Pivotal Trial in Diabetic Cardiomyopathy (DbCM) () - May 18, 2020 - Abstract #ADA2020ADA_3446;
P3
No clinically relevant changes in liver and kidney function were reported [Table].The study results support further clinical development to explore potential use of AT-001 as an emerging therapeutic strategy in preventing diabetes complications. A pivotal phase 2/3 study, ARISE-HF (NCT04083339) was initiated to evaluate the safety and efficacy of two doses of AT-001 vs. placebo to improve or prevent the decline of functional capacity in adults with DbCM.
- AT-001 / Applied Therap
[VIRTUAL] AT-001, a Next Generation Aldose Reductase Inhibitor with Improved Selectivity and Specificity, Protects from Cellular Damage Associated with Hyperglycemia () - May 18, 2020 - Abstract #ADA2020ADA_2281;
AT-001 effectively prevented cellular damage caused by oxidative stress under hyperglycemic conditions warranting further investigation of AT-001 in the treatment of diabetic complications. AT-001 is currently being evaluated in a pivotal phase 2/3 study (ARISE-HF NCT 04083339) to treat diabetic cardiomyopathy and prevent progression to overt heart failure and also includes sub-analyses for retinopathy and diabetic peripheral neuropathy.
- AT-001 / Applied Therap
[VIRTUAL] Addressing the Safety Challenges of Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy, a Potent and Selective Next Generation Aldose Reductase Inhibitor () - May 18, 2020 - Abstract #ADA2020ADA_1857;
The unique structure and activity of AT-001 provide potent selectivity for Aldose Reductase and lack of off-target effects. The in-vitro safety of this agent together with the positive safety data from the phase 1/2 program, supports the ongoing pivotal study in DbCM.
- | caficrestat (AT-001) / Applied Therap
New P2 trial: Cardiovascular Effects of COVID-19 (clinicaltrials.gov) - Apr 27, 2020
P2, N=500, Recruiting, Sponsor: NYU Langone Health
- AT-001 / Applied Therap, ATL 001 / Achilles Therap
ATL001 (STARLIGHT BALLROOM) - Feb 21, 2020 - Abstract #IASLCLCTT2020IASLC_LCTT_113;
- | AT-007 / Applied Therap, AT 005 / Androclus
Journal: Comparison of Two Series Elastic Actuator Designs Incorporated into a Shoulder Exoskeleton. (Pubmed Central) - Jan 18, 2020
For arm rotation, the step response rise time was.03 s, and impedance peaked at.023 Nm/deg during 3.5 Hz oscillations. Both SEA designs had performance measurements that were similar to other SEA designs in terms of torque tracking, but with much lower impedance than previously reported.
- | caficrestat (AT-001) / Applied Therap
Enrollment open: ARISE-HF: Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy (clinicaltrials.gov) - Oct 15, 2019
P3, N=675, Recruiting, Sponsor: Applied Therapeutics, Inc.
Both SEA designs had performance measurements that were similar to other SEA designs in terms of torque tracking, but with much lower impedance than previously reported. Not yet recruiting --> Recruiting
- | govorestat (AT-007) / Applied Therap
New P1/2 trial: Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia (clinicaltrials.gov) - Oct 6, 2019
P1/2, N=86, Recruiting, Sponsor: Applied Therapeutics, Inc.